September - 2025

top of page

MECFA Blog

News & Articles

Lipidome profile of Cystic Fibrosis Related Diabetes, Type 1 and Type 2 Diabetes Mellitus: potential links to inflammation and glucose and lipid metabolism.

Alessandra Mingione, Cristian Loretelli, Michele Dei Cas, Francesca Pivari, Matteo Barcella, Ivan Merelli, Aida Zulueta, Rita Paroni,...

Featured Posts

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

A case for improved carrier screening

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

The search for molecular glue in targeted disease control

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p

Recent Posts

Lipidome profile of Cystic Fibrosis Related Diabetes, Type 1 and Type 2 Diabetes Mellitus: potential links to inflammation and glucose and lipid metabolism.

CFTR profiles and phenotypic associations in Pakistani children and adults with suspected cystic fibrosis

Trial tests new approach with CFTR modulators for cystic fibrosis

Change in pulmonary pathogens three years after elexacaftor/tezacaftor/ivacaftor: an observational study in the Danish cystic fibrosis cohort

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Early data from ARCT-032 clinical trial for CF expected next month

CF lung inflammation persists after treatment due to stubborn bacteria

After the earthquake: Unmet needs in people with cystic fibrosis in Turkiye- multicenter study

Breathing New Hope: How Jordan is Rewriting the Story of Cystic Fibrosis Care

Tobacco Smoke Adversely Affects Sustained Benefits of ETI in Cystic Fibrosis

Archive

Search By Tags

bottom of page